News from amsterdam molecular therapeutics b.v A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

06 Sep, 2011, 06:00 BST Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health

Gains US Patent Protection for Proprietary AAV Intellectual Property Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human ...


25 Aug, 2011, 06:00 BST Amsterdam Molecular Therapeutics Reports Half-Year Results 2011

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of...


08 Jul, 2011, 06:00 BST Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for...


06 Jul, 2011, 06:00 BST Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced the appointment of Dr. Carlos R....


29 Jun, 2011, 06:00 BST Amsterdam Molecular Therapeutics' Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients

Data Presented at the 79thEuropean Atherosclerosis Society Meeting Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human...


24 Jun, 2011, 06:00 BST Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application

- Dossier Re-Examination Process Initiated Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today...


23 May, 2011, 06:00 BST Amsterdam Molecular Therapeutics Research Demonstrates AAV Delivery May Be Key Success Factor for Therapeutic Promise of RNAi

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today the results from studies exploring the ...


20 May, 2011, 06:00 BST Amsterdam Molecular Therapeutics Presents Data Supporting Role of Chylomicron Clearance as Marker for Glybera(R) Efficacy

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today results from a long-term efficacy...


19 May, 2011, 06:00 BST AMT Provides Business Update for the First Quarter 2011

Amsterdam Molecular Therapeutics (Euronext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business...


10 May, 2011, 06:00 BST Amsterdam Molecular Therapeutics Provides Status Update on Glybera(R)

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, provided today a status update on Glybera (alipogene...


23 Mar, 2011, 16:43 GMT AMT Notice of Annual General Meeting

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in human gene therapy, announced that it will host its Annual General Meeting at its...


07 Mar, 2011, 06:00 GMT AMT Receives Grant From Dutch Parents Organization for Duchenne Muscular Dystrophy Gene Therapy

Amsterdam Molecular Therapeutics (AMT) (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Duchenne Parent...


04 Mar, 2011, 19:31 GMT Amsterdam Molecular Therapeutics 2010 Annual Report

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, published today its 2010 Annual Report. It is...


16 Feb, 2011, 11:13 GMT /C O R R E C T I O N -- Amsterdam Molecular Therapeutics B.V/

In the news release, "Amsterdam Molecular Therapeutics Reports Full Year Results 2010" issued on 16 Feb 2011 06:00 GMT, by Amsterdam Molecular...


16 Feb, 2011, 06:00 GMT Amsterdam Molecular Therapeutics Reports Full Year Results 2010

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December...


31 Jan, 2011, 06:00 GMT AMT Receives EUR 1.1 Million Funding for Acute Intermittent Porphyria Gene Therapy as part of EU Consortium Grant

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Union (EU) has...


10 Jan, 2011, 06:00 GMT AMT to Supply cGMP Manufacturing to Consortium Led by Institut Pasteur for Clinical Development of Gene Therapy for Rare Genetic Disorder in Children

- AMT Gains Option to Acquire Commercial Rights to Sanfilippo B Gene Therapy Product Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in...